FDA treads carefully on molecular diagnostics
Last week, the FDA tried to better define its role in molecular testing. The agency approved Memorial Sloan Kettering’s MSK-IMPACT, which profiles 468 genes to assess solid tumors, as an in vitro diagnostic (IVD). In addition, it elevated the New York State Department of Health as a third-party reviewer for IVDs.
No hay comentarios:
Publicar un comentario